Journal September 25, 2026 5 min read

What Does the Research Say About Intermittent Fasting?

A review of registered clinical studies examining intermittent fasting, time-restricted eating, and related metabolic interventions across pancreatitis, mitochondrial dynamics, type 2 diabetes, prostate cancer, obesity,

peptides-pro Editorial

Intermittent fasting (IF) is an umbrella term for eating patterns that cycle between periods of voluntary fasting and eating. Common protocols include 16:8 time-restricted feeding (TRE), alternate-day fasting, and Ramadan dry fasting. The research literature centres on nutrient-sensing pathways, particularly insulin signalling, AMP-activated protein kinase (AMPK), and sirtuin-dependent mitochondrial quality control.

Registered studies have examined IF in populations including pancreatitis patients, type 2 diabetes patients, prostate cancer patients undergoing androgen deprivation therapy, obese women, and healthy adults using wearable technology. Outcomes measured include body composition, lipid profile, glycemic control, liver enzymes, inflammatory biomarkers, mitochondrial DNA markers, and oral health indices.

Research Studies

Intermittent fasting and pancreatitis-related quality of life

A registered clinical study compares intermittent fasting with a standard diet approach for improving quality of life related to pancreas disease. The stated purpose is to improve symptoms and prevent hospitalisation for pancreas-related issues [1]. This is a clinical trial protocol; results are not yet reported in the evidence block.

Mitophagy and mitochondrial DNA dynamics during Ramadan dry fasting versus 16:8 time-restricted feeding

A study investigates how different fasting types affect cellular health, focusing on mitochondrial clearance and renewal. Ramadan dry fasting involves total restriction of food and fluids from dawn to sunset, whereas standard intermittent fasting permits water intake. The researchers hypothesise that the combined effects of fluid restriction and natural daily body rhythms during Ramadan may trigger a stronger mitophagy response compared with 16:8 water-permitted fasting. Blood markers related to mitochondrial DNA and metabolic health are assessed across a 30-day period [2].

Time-restricted eating and GLP1 receptor agonists in prostate cancer patients on androgen deprivation therapy

A phase II trial compares time-restricted eating and GLP1 receptor agonists (semaglutide and tirzepatide) with an American Heart Association heart-healthy diet intervention. The population is prostate cancer patients undergoing androgen deprivation therapy (ADT), who are at increased cardiovascular risk due to treatment-related metabolic changes including weight gain, increased body fat, and insulin resistance [4].

Intervention	Comparator	Population	Primary focus
Time-restricted eating (TRE)	AHA heart-healthy diet	Prostate cancer patients on ADT	Cardiovascular and metabolic health
GLP1 receptor agonists (semaglutide, tirzepatide)	AHA heart-healthy diet	Prostate cancer patients on ADT	Cardiovascular and metabolic health

Intermittent fasting versus frequent feeding for weight loss in obese women

A 12-week study compared a 16:8 time-restricted feeding protocol plus home-based exercise with a calorie-restricted standard diet plus home-based exercise in obese women. Outcomes included body composition, lipid profile, glycemic control, and liver function enzyme levels [6].

Intermittent fasting and oral health: inflammatory biomarkers and periodontal measures

A study investigated the impact of short-term ketogenic diet and intermittent fasting on oral health in an Iraqi population. Measured outcomes included gingivitis severity, plaque index, salivary flow and pH, and salivary levels of C-reactive protein, IL-6, TNF-alpha, and LL-37 peptide [8].

Wearable-monitored intermittent fasting for human optimization: an N-of-1 study

A prospective N-of-1 study examines correlations between continuous glucose monitoring and an individual's metabolic health and overall well-being during a human optimization program. The background notes interest in intermittent fasting for weight management, energy production, and metabolic well-being, and its potential to reduce systemic inflammation and help prevent chronic diseases. The study also considers whether athletes can sustain performance during fasting periods [7].

Intermittent fasting and the Snouda Metabolic Score for type 2 diabetes phenotyping

A study tests the Snouda Metabolic Score (SMS), a tool that classifies type 2 diabetes patients into metabolic phenotypes based on five body systems: insulin resistance, chronic inflammation, hormonal disruption, gut microbiome imbalance, and mitochondrial dysfunction. Participants then follow a personalised 24-week lifestyle and nutritional protocol targeting their specific phenotype, which includes dietary changes, structured exercise, and targeted nutritional supplementation [3]. Intermittent fasting is not specified as the sole intervention in this protocol.

Probiotic intervention and weight regain in weight cyclers

A study evaluates the potential of probiotics in obesity management, specifically their impact on weight regain after caloric restriction. The background notes that gut microbiota play a critical role in weight management and that probiotics may reduce weight regain by modulating appetite and metabolism [5]. This study does not test intermittent fasting directly but addresses metabolic adaptations following caloric restriction, a context relevant to fasting research.

Alternate-day fasting and leptin sensitivity: epigenetic regulation in the hypothalamus

Preclinical work reports that alternate-day fasting enhances leptin sensitivity via JMJD3-dependent epigenetic regulation of the leptin receptor (LepRb) in the hypothalamus. Leptin resistance is described as a hallmark of obesity, characterised by diminished responsiveness to leptin and disrupted energy homeostasis. Transcriptional repression of LepRb is identified as a critical defect impairing downstream signal transduction [9]. This finding is from animal or cell-based models and has not been confirmed in human trials within the evidence block.

Intermittent fasting and gut-endocrine axis responses to Senna alexandrina in obese rats

An animal study reports that intermittent fasting amplifies gut-endocrine axis responses to Senna alexandrina supplementation in obese rats. Obesity was induced by high-fat, high-sucrose diets, which disrupt lipid metabolism, glucose homeostasis, and gut microbial balance. The study examines whether Senna alexandrina, traditionally used for other purposes, can restore metabolic regulation when combined with intermittent fasting [10]. This is an animal-only finding.

If you are reading this for personal health reasons

The materials and information described here are for laboratory research only. We do not provide dosing, medical guidance, or personal health advice. Anyone considering intermittent fasting or any related intervention for themselves should speak to a licensed clinician.